Coverage contingent on code-specific selection criteria

Selected CPT/HCPCS/HCPCS codes are covered only when the policy's specified clinical selection criteria are met; some codes are explicitly listed as not covered for indications in this policy.

• See CPT/HCPCS list (e.g., 0421T, 52282, 52649, 53854, 37242-37244, 53855) — coverage contingent on meeting policy criteria.

PAE: prior therapy and documentation for authorization

For prostatic artery embolization (PAE) requests, prior authorization should confirm failure of medical therapy for at least 6 months and include objective baseline measures and counseling on alternatives.

• Document trial of medical therapy ≥6 months.
• Provide objective measures: IPSS, QOL, Qmax, prostate volume, PSA.
• Document shared decision-making including discussion of TURP, HoLEP, and other surgical options.

PUL (UroLift) — document trial-based candidacy

Authorization for prostatic urethral lift (PUL/UroLift) should document trial-like inclusion criteria: AUASI/IPSS ≥13, prostate volume 30–80 cc, and Qmax ≤12 mL/sec.

• Age ≥50 per trial populations.
• Document counseling on alternatives and desire to preserve sexual function.

Rezūm — prior authorization to confirm trial-based eligibility

Rezūm reimbursement decisions often require documentation that the patient meets trial eligibility (e.g., age ≥50, IPSS ≥13, Qmax ≤15 mL/s, prostate volume 30–80 cc); prior authorization is recommended to confirm these criteria.

• Provide baseline IPSS, Qmax, and prostate volume to align with RCT inclusion.

No explicit mandatory prior-authorization code list in excerpt

The document does not specify a mandatory prior-authorization code list or payer-level PA rules for all procedures in this excerpt.

• Evidence summaries and guideline statements are provided, but no explicit payer PA mandates are listed in these chunks.

PAE candidates — document prior therapy and prostate size

When requesting PAE authorization, document prior medical therapy attempts and prostate size, as many studies enrolled patients with moderate-to-severe LUTS refractory to medical therapy and large prostate volumes (often ≥80–100 cm3).

• Include duration and agents of prior medical therapy and measured prostate volume (e.g., ≥80 cm3 when applicable).

PAE prior authorization — trial/context documentation may be required

Because PAE is considered experimental/emerging by some authorities, prior authorization may require documentation of clinical trial enrollment or other justification that the patient is a poor surgical candidate.

• If not performed in a trial, provide rationale (e.g., surgical contraindication, inability to stop anticoagulation).

Use study inclusion/exclusion to inform prior-authorization review

Clinical inclusion and exclusion criteria used in trials (IPSS, Qmax, prostate volume, absence of excluded conditions) can inform prior-authorization review where applicable.

• Authorization reviewers should verify study-like criteria when used as clinical benchmarks for coverage decisions.

Volume-based prior-authorization guidance for Aquablation

Aquablation prior-authorization considerations should note that trials generally evaluated prostates approximately 30–80 mL (with separate studies for 80–150 mL); document measured prostate volume to match studied ranges.

• Provide prostate volume measurement and indicate which trial population (30–80 mL or 80–150 mL) the patient aligns with.

Prior-authorization requirements not specified in this section

This section of the document does not list specific prior-authorization requirements for some procedures; note absence of explicit PA rules in the referenced excerpts.

• Clinical trial protocols and follow-up schedules are described, but no payer PA mandates are specified here.

PA: prior authorization should match study inclusion/exclusion

Prior authorization should verify that the patient meets the studied inclusion/exclusion criteria (e.g., IPSS ≥10, Qmax <12 mL/s, prostate volume within studied limits, absence of enlarged median lobe or urinary retention) when coverage is conditioned on trial-like evidence.

• Confirm absence of exclusions such as PVR >250 mL, obstructive median lobe, hemostatic disorders, or prior prostate surgery when applicable.

No PA rules specified in bibliographic excerpts

No prior-authorization requirements are specified in the bibliographic/reference excerpts provided here.

• Content in these chunks is bibliographic; administrative PA rules are not stated.

No explicit PA requirements listed in these chunks

Policy sections list no specific prior-authorization requirements for the document chunks referenced; reviewers should refer to payer administrative resources for PA rules.

• Policy history and review dates are provided, but no CPT list requiring PA is given in these chunks.

Confirm trials of medical therapy (alternatives to TURP)

Medical therapy options (alpha-blockers, 5‑alpha‑reductase inhibitors, tadalafil) are listed as medically necessary alternatives to TURP and are expected to be considered prior to procedural interventions when clinically appropriate.

• Document trials of medical therapy when claiming failure or intolerance prior to procedures where step therapy is expected.

Medical therapy generally first-line before procedures

Conservative and medical therapy are first-line for BPH; minimally invasive procedures are generally considered after inadequate response to medical management.

• Ensure documentation of inadequate response to or intolerance of medical therapy before pursuing procedural options when applicable.

Document trials of available medical regimens before procedural claims

Medical therapy is the usual initial approach; newer agents and combinations (e.g., alpha-blockers, PDE5 inhibitors, mirabegron) are options before invasive therapies and should be documented if used.

• Record agents tried, duration, response, and tolerability in the chart for prior-therapy review.

WVTT may be considered early clinically — no formal step mandate

WVTT (Rezūm) clinical commentary suggests it may be considered earlier as an alternative to pharmaceuticals or more invasive surgery for eligible men, but no formal step-therapy mandate is specified.

• Providers may discuss WVTT as an option earlier in shared decision-making, documenting rationale.

Step: document medical therapy trial before PAE

Before considering PAE, document that medical therapy was tried and either failed or was not tolerated, as PAE is positioned between medical therapy and surgery in treatment pathways.

• Include duration and agents of prior medical therapy and reasons for failure or intolerance.

Document discussion of standard surgical alternatives before PAE

Society statements recommend considering PAE for select patients (very large prostate, surgical contraindication) after discussion of standard surgical options; document that alternatives were reviewed.

• Document shared decision-making and rationale for selecting PAE over standard surgical options.

No explicit step-therapy sequencing specified

This document does not specify formal step-therapy sequencing requirements; absence of specified sequencing means plan-level rules should be checked for any local step edits.

• Verify with payer administrative rules for any plan-specific step edits.

Document discussion of standard surgical alternatives for Aquablation

When considering Aquablation, providers should document consideration of standard surgical alternatives (TURP, HoLEP) and shared decision-making prior to Aquablation.

• Include documented counseling on risks, benefits, and limited long‑term durability data compared with standard options.

Document research/protocol context when offering Aquablation or Rezūm

Guidelines and reviews note Aquablation and Rezūm remain under evaluation and may be offered in research contexts; document if procedures are performed as part of research or registries.

• When used in research settings, include trial identifiers and enrollment documentation.

No step-therapy sequencing specified in excerpts

No consistent sequencing of step-therapy is specified in these excerpts; check payer-specific requirements for any enforced sequencing.

• Clinical judgment and local payer rules determine sequencing when not defined by policy.

Ensure documentation supports medical necessity and code indications

Documentation should support that the selected procedure meets the policy's medical necessity criteria (e.g., age, prostate length for UroLume; indication consistent with covered CPT/HCPCS/ICD-10 codes).

• Include age, symptomatic indication, prostate measurements, and prior therapies to substantiate medical necessity.

Document required clinical measures (IPSS, Qmax, PVR, prostate volume, PSA)

Required clinical measures to document before and after procedures include validated symptom scores (IPSS/AUA), quality-of-life measures, uroflowmetry (Qmax), post-void residual, prostate volume, and PSA.

• Baseline and follow-up IPSS/AUA, QoL, Qmax, PVR, prostate volume, and PSA should be recorded.
• Use validated sexual function measures (IIEF/MSHQ) when preservation of sexual function is relevant.

Document trial-like eligibility elements (age, IPSS, Qmax) for authorization

Trial eligibility elements commonly documented in studies include age ≥50, IPSS ≥13 (moderate-to-severe LUTS), and Qmax thresholds (e.g., ≤15 mL/s for Rezūm); include these when applicable to support authorization.

• Provide age, baseline IPSS, Qmax, and prostate volume consistent with cited study criteria.

Document diagnostic testing (PVR, ultrasound, uroflowmetry, pressure-flow studies) as indicated

Diagnostic testing useful to support treatment decisions includes post-void residual measurement, prostate ultrasound, uroflowmetry (Qmax), and pressure-flow studies when indicated; document results when used to justify intervention.

• Ensure voided volume >150 mL for reliable uroflowmetry and consider bladder scan pre-void volume >250 mL when needed.

Document outcome measures (IPSS, QoL, Qmax, PVR, PV, PSA, sexual function)

Required clinical outcome documentation for procedures includes validated symptom scores (IPSS), QoL, objective measures (Qmax, PVR, prostate volume), PSA, and sexual function assessments; capture these baseline and follow-up data.

• Report perioperative complications and follow-up assessments at intervals (e.g., 1, 3, 6 months, and annually up to 3 years when available).

Suggested documentation elements for PAE candidacy

Suggested documentation to support PAE candidacy includes prostate volume, symptom scores (IPSS, QoL), Qmax, PVR, comorbidity indices, prior treatments, and informed consent discussing trade-offs.

• Include Charlson comorbidity index or other measures of surgical risk when relevant.

Document trial-specified thresholds (IPSS ≥10, Qmax ≤12 mL/s, prostate volume limits)

Clinical evidence elements commonly used in trials that can inform documentation include baseline IPSS ≥10, Qmax ≤12 mL/s (often <12 mL/s in earlier studies), and prostate volume limits (e.g., TIND <60 mL, iTIND <75 mL).

• When using trial criteria as benchmarks, explicitly document how the patient's measures align with those thresholds.

Capture trial-standard baseline and follow-up measures (IPSS, Qmax, PSA, sexual function)

Suggested clinical documentation elements include baseline IPSS, Qmax, PSA, sexual function (MSHQ/IIEF), uroflowmetry, and retreatment rates up to 2–3 years; include these elements for comprehensive authorization review.

• Capture follow-up data on retreatment and complications to support ongoing coverage decisions.

Document adherence to trial-like follow-up schedules when used to support therapy

Randomized trial protocols and follow-up schedules are described (e.g., Aquablation trials with follow-up up to 5 years); when applicable, document adherence to follow-up schedules used in trials.

• Provide scheduled follow-up assessments consistent with trial protocols when used to substantiate coverage.

Required clinical documentation: baseline measures, perioperative and follow-up data

Clinical documentation submitted for authorization should include baseline IPSS, Qmax, prostate volume, perioperative complications, and follow-up assessments at standard intervals (1, 3, 6 months and annually up to 3 years when available).

• Report perioperative details and any device implantation/removal timing when relevant (e.g., iTIND removal at 5–7 days).

Denial risk: investigational/experimental procedures/devices

Procedures or devices listed as experimental and investigational in this policy (e.g., temporary prostatic urethral stent, prostatic arterial embolization in some contexts, botulinum toxin) are considered not established and would be denied as not medically necessary when submitted outside investigational exceptions.

• Do not expect routine coverage for items explicitly listed as investigational without trial context or exceptional justification.

Denial risk increased when evidence or documentation is inadequate

Procedures reported as experimental or lacking long-term outcomes (for example, PAE in small series) have higher denial risk when submitted without adequate documentation of prior medical therapy failure and objective symptom measures.

• Insufficient documentation of prior therapy or objective measures increases likelihood of denial for experimental interventions.

Evidence gaps may trigger requests for additional data or denials

Lack of high-quality, consistent data and heterogeneity in reporting for some procedures (notably PAE) may trigger requests for additional clinical data or result in coverage denial.

• Be prepared to supply detailed outcome data and standardized measures if requested during review.

PAE may be denied without trial context or robust justification

PAE is considered experimental by some authoritative reviews and the AUA recommends performance only in the context of clinical trials; lack of trial context or inadequate evidence may lead to noncoverage or denial.

• If PAE is proposed outside a trial, include justification such as being a poor surgical candidate and detailed risk/benefit discussion.

Study exclusion criteria (iTIND) — may affect authorization

Study exclusion criteria used in iTIND trials (hemostatic disorders, PVR >250 mL, obstructive median lobe, prior prostate surgery) are relevant to authorization; presence of these conditions may affect candidacy and could lead to denial.

• Verify and document absence of these exclusionary conditions when seeking coverage for iTIND-like procedures.

NICE: Aquablation use only with special arrangements — potential denial risk otherwise

NICE recommends Aquablation be used only with special arrangements because efficacy evidence is limited; lack of required research arrangements locally could lead to determinations limiting routine use.

• Document research protocol participation or local data collection arrangements if relying on NICE-type special‑arrangement pathways.

Populations excluded from studies may be at risk for non-coverage

Studies often excluded patients with enlarged median lobes, PVR >250 mL, urinary retention, or those on anticoagulant/antiplatelet therapy; these populations may be at risk for non-coverage where evidence is lacking.

• Document alternative justification or trial enrollment if treating excluded populations.